Overview

A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments

Status:
Active, not recruiting

Trial end date:
2023-04-19

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active polymyositis (PM)/dermatomyositis (DM) despite receiving 1 or more standard-of-care treatments (for example, glucocorticoids and/or immunomodulators).

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Pharmaceutical K.K.

Treatments:

Ustekinumab